Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00775502 · ClinicalTrials.gov registry record · Phase 1
Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma
A Phase 1 study, sponsored by Kyowa Kirin Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT00775502 is a Phase 1 study that was terminated before completion, run by Kyowa Kirin Co.. The registered enrollment target is 23 participants.
The verdict
NCT00775502, a Phase 1 study, was terminated before completion, sponsored by Kyowa Kirin Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
This study will test the ability of a specially designed monoclonal antibody to destroy multiple myeloma cells. This antibody is unique in its ability to promote the death of multiple myeloma cells by processes known as antibody dependent cellular cytotoxicity (ADCC)and complement dependent cytotoxicity (CDC). The study is designed to determine both the optimal dose of the antibody to destroy multiple myeloma cells and frequency of dosing.
Interventions
- DRUG BIW-8962
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2008-10 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00775502
The ClinicalTrials.gov registry entry for NCT00775502 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyowa Kirin Co., which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BIW-8962 is the first listed.
NCT00775502 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00775502 about?
NCT00775502 is a clinical study titled "Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma". This study will test the ability of a specially designed monoclonal antibody to destroy multiple myeloma cells. This antibody is unique in its ability to promote the death of multiple myeloma cells by processes known as antibody dependent cellular cytotoxicity (ADCC)and complement dependent cytotoxi...
What is the current status of trial NCT00775502?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2008-10. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00775502?
The interventions under investigation include: BIW-8962 (DRUG).
Who is sponsoring clinical trial NCT00775502?
This trial is sponsored by Kyowa Kirin Co., which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.